Cyteir Therapeutics Inc

NASDAQ CYT

Data sourced from

and

Download Data

Cyteir Therapeutics Inc Working Capital To Sales Ratio for the quarter ending September 30, 2023

Cyteir Therapeutics Inc Working Capital To Sales Ratio is NA for the quarter ending September 30, 2023. The working capital to sales ratio measures the proportion of working capital to revenue. It is calculated by dividing the difference between current assets and current liabilities by revenue. This ratio provides insights into the efficiency of working capital utilization relative to revenue generation. A higher ratio suggests better utilization of working capital to generate sales revenue.

NASDAQ: CYT

Cyteir Therapeutics Inc

CEO	Mr. Joseph S. Zakrzewski
IPO Date	June 18, 2021
Location	United States
Headquarters	128 Spring Street, Lexington, MA, United States, 02421
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Key trends